more

CONMED (CNMD)

(Delayed Data from NYSE)

$74.72 USD

-0.78 (-1.03%)

Updated May 17, 2024 04:00 PM ET

After-Market: $74.75 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.08%
2	Buy	17.91%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.55%
S&P	500	11.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

Bottom 41% (146 out of 249)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues

by Zacks Equity Research Published on March 04,2019

OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.

Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on March 04,2019

Penumbra (PEN) sees strength across all segments in Q4.

Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on March 01,2019

Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.

medical

Patterson Companies (PDCO) Earnings Match Estimates in Q3

by Zacks Equity Research Published on February 28,2019

Patterson Companies (PDCO) gains from solid segmental contributions in Q3.

Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4

by Zacks Equity Research Published on February 28,2019

At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.

Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall

by Zacks Equity Research Published on February 28,2019

Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.

earnings

Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates

by Zacks Equity Research Published on February 27,2019

The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q4

by Zacks Equity Research Published on February 27,2019

The year-over-year improvement in Insulet's (PODD) Q4 results on solid uptake of Omnipod system in the United States is encouraging. The company also gains from direct European operations.